The Medicines and Healthcare products Regulatory Agency (MHRA) recently launched a toolkit for healthcare professionals (HCPs) regarding sodium valproate in order to communicate its teratogenic effects. The CEU recommends that all HCPs be prepared to provide information about and access to effective contraception for women who have undergone treatment with valproate-related medicines.
This statement aims to encourage the consistent and safe management of women requesting intrauterine contraception (IUC) and subdermal implants (SDI) who are taking anticoagulants or antiplatelet medications. It is primarily aimed at clinicians working in primary care and community sexual and reproductive health clinics.
This statement provides guidance on contraceptive choices for transgender and non-binary people and their partners, who are engaging in vaginal sex where there is a risk of pregnancy. The statement also offers general sexual health advice for these groups.